Leerink Partnrs Has Positive Outlook of LRMR FY2026 Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Investment analysts at Leerink Partnrs upped their FY2026 earnings estimates for Larimar Therapeutics in a report released on Monday, June 23rd. Leerink Partnrs analyst J. Park now forecasts that the company will post earnings of ($2.21) per share for the year, up from their prior forecast of ($2.61). The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.15) per share. Leerink Partnrs also issued estimates for Larimar Therapeutics' FY2027 earnings at ($1.82) EPS and FY2028 earnings at ($0.94) EPS.

LRMR has been the subject of several other reports. HC Wainwright upped their price target on Larimar Therapeutics from $15.00 to $16.00 and gave the stock a "buy" rating in a research note on Tuesday, March 25th. Citigroup reissued a "buy" rating on shares of Larimar Therapeutics in a research report on Tuesday, June 24th. Wedbush decreased their price objective on shares of Larimar Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a research note on Tuesday, June 24th. Robert W. Baird reduced their target price on shares of Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating on the stock in a report on Tuesday, March 25th. Finally, Guggenheim restated a "buy" rating and set a $26.00 target price on shares of Larimar Therapeutics in a report on Tuesday, June 24th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Larimar Therapeutics presently has an average rating of "Buy" and an average price target of $18.50.

Larimar Therapeutics Trading Down 1.6%

Shares of LRMR traded down $0.05 during mid-day trading on Thursday, reaching $3.03. The company had a trading volume of 1,913,731 shares, compared to its average volume of 836,795. The stock has a market cap of $194.01 million, a price-to-earnings ratio of -2.03 and a beta of 0.79. The firm has a fifty day simple moving average of $2.41 and a 200-day simple moving average of $2.86. Larimar Therapeutics has a fifty-two week low of $1.61 and a fifty-two week high of $11.20.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last released its earnings results on Wednesday, April 30th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04).

Hedge Funds Weigh In On Larimar Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new position in Larimar Therapeutics in the 4th quarter valued at about $25,000. Walleye Capital LLC acquired a new position in shares of Larimar Therapeutics in the 1st quarter valued at approximately $37,000. Algert Global LLC acquired a new position in shares of Larimar Therapeutics in the 4th quarter valued at approximately $47,000. Graham Capital Management L.P. acquired a new position in shares of Larimar Therapeutics in the 4th quarter valued at approximately $54,000. Finally, ProShare Advisors LLC acquired a new position in shares of Larimar Therapeutics in the 4th quarter valued at approximately $58,000. 91.92% of the stock is owned by hedge funds and other institutional investors.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.